Literature DB >> 21602702

Hepatic lipid peroxidation and cytochrome P-450 2E1 in pediatric nonalcoholic fatty liver disease and its subtypes.

Lauren N Bell1, Jean P Molleston, Michael J Morton, Ann Klipsch, Romil Saxena, Raj Vuppalanchi, Naga Chalasani.   

Abstract

GOAL: To compare hepatic lipid peroxidation and cytochrome P-450 2E1 (CYP2E1) protein content in liver biopsies from children with nonalcoholic fatty liver disease (NAFLD) and 2 control groups.
BACKGROUND: Elevated hepatic lipid peroxidation resulting from increased hepatic CYP2E1 enzyme activity is involved in the pathogenesis of NAFLD and nonalcoholic steatohepatitis (NASH) in adults, but studies in children are lacking. STUDY: Liver biopsies from 59 children with NAFLD (49 with NASH), 10 children with normal liver histology, and 9 children with mild chronic hepatitis C (HCV) infection were examined. Hepatic malondialdehyde (a measure of lipid peroxidation) levels and CYP2E1 protein content were quantitated, as a percentage of the total area, by immunohistochemical staining of liver biopsy material followed by digital image quantitation.
RESULTS: Lipid peroxidation was significantly greater in NAFLD liver biopsies (46.7 ± 20.8%) compared with biopsies from children with normal liver histology (7.6 ± 9.4%; P<0.001) or HCV infection (7.7 ± 7.6%; P<0.001). However, hepatic CYP2E1 expression was not different across the NAFLD, normal liver histology, and HCV groups (60.7 ± 8.7%, 53.5 ± 10.7%, and 60.0 ± 11.9%, respectively; P=0.116). Among children with NAFLD, lipid peroxidation and CYP2E1 protein content did not differ between biopsies with and without NASH. Body mass index was independently associated with hepatic lipid peroxidation levels (r=0.549; P<0.001).
CONCLUSIONS: Hepatic lipid peroxidation is increased in children with NAFLD but this is not related to hepatic CYP2E1 expression. No difference in lipid peroxidation in pediatric NAFLD versus NASH argues against a role in disease progression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21602702      PMCID: PMC5300763          DOI: 10.1097/MCG.0b013e31821377e4

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  35 in total

1.  Controversies in the management of pediatric liver disease: Hepatitis B, C and NAFLD: Summary of a single topic conference.

Authors:  Benjamin L Shneider; Regino González-Peralta; Eve A Roberts
Journal:  Hepatology       Date:  2006-11       Impact factor: 17.425

2.  Bariatric surgery-induced weight loss reduces hepatic lipid peroxidation levels and affects hepatic cytochrome P-450 protein content.

Authors:  Lauren N Bell; Constance J Temm; Rashmil Saxena; Raj Vuppalanchi; Philip Schauer; Mordechai Rabinovitz; Alyssa Krasinskas; Naga Chalasani; Samer G Mattar
Journal:  Ann Surg       Date:  2010-06       Impact factor: 12.969

3.  Human cytochrome P450 maximal activities in pediatric versus adult liver.

Authors:  J G Blanco; P L Harrison; W E Evans; M V Relling
Journal:  Drug Metab Dispos       Date:  2000-04       Impact factor: 3.922

4.  Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation.

Authors:  M D Weltman; G C Farrell; C Liddle
Journal:  Gastroenterology       Date:  1996-12       Impact factor: 22.682

5.  Oxidative stress and antioxidant defenses in serum of patients with non-alcoholic steatohepatitis.

Authors:  Gulden Baskol; Mevlut Baskol; Derya Kocer
Journal:  Clin Biochem       Date:  2007-03-16       Impact factor: 3.281

6.  Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network.

Authors:  Elizabeth M Brunt; David E Kleiner; Laura A Wilson; Aynur Unalp; Cynthia E Behling; Joel E Lavine; Brent A Neuschwander-Tetri
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

7.  Robustness of chlorzoxazone as an in vivo measure of cytochrome P450 2E1 activity.

Authors:  Lena Ernstgård; Margareta Warholm; Gunnar Johanson
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

8.  Human hepatic CYP2E1 expression during development.

Authors:  Elizabeth K Johnsrud; Sevasti B Koukouritaki; Karthika Divakaran; Laura L Brunengraber; Ronald N Hines; D Gail McCarver
Journal:  J Pharmacol Exp Ther       Date:  2003-10       Impact factor: 4.030

Review 9.  The free radical theory of aging.

Authors:  Denham Harman
Journal:  Antioxid Redox Signal       Date:  2003-10       Impact factor: 8.401

10.  Oxidative stress and enzymatic antioxidant status in patients with nonalcoholic steatohepatitis.

Authors:  Mehmet Koruk; Seyithan Taysi; M Cemil Savas; Omer Yilmaz; Fatih Akcay; Metin Karakok
Journal:  Ann Clin Lab Sci       Date:  2004       Impact factor: 1.256

View more
  9 in total

Review 1.  Role of CYP2E1 in Mitochondrial Dysfunction and Hepatic Injury by Alcohol and Non-Alcoholic Substances.

Authors:  Mohamed A Abdelmegeed; Seung-Kwon Ha; Youngshim Choi; Mohammed Akbar; Byoung-Joon Song
Journal:  Curr Mol Pharmacol       Date:  2017       Impact factor: 3.339

2.  A case-control study on the effect of metabolic gene polymorphisms, nutrition, and their interaction on the risk of non-alcoholic fatty liver disease.

Authors:  Luca Miele; Valentina Dall'armi; Consuelo Cefalo; Bojan Nedovic; Dario Arzani; Rosarita Amore; Gianlodovico Rapaccini; Antonio Gasbarrini; Walter Ricciardi; Antonio Grieco; Stefania Boccia
Journal:  Genes Nutr       Date:  2014-01-09       Impact factor: 5.523

Review 3.  Controversy in the diagnosis of pediatric non-alcoholic fatty liver disease.

Authors:  Pierluigi Marzuillo; Anna Grandone; Laura Perrone; Emanuele Miraglia Del Giudice
Journal:  World J Gastroenterol       Date:  2015-06-07       Impact factor: 5.742

4.  Association between serum α-L-fucosidase and non-alcoholic fatty liver disease: Cross-sectional study.

Authors:  Zhen-Ya Lu; Chao Cen; Zhou Shao; Xin-Hua Chen; Cheng-Fu Xu; You-Ming Li
Journal:  World J Gastroenterol       Date:  2016-02-07       Impact factor: 5.742

Review 5.  Biomarkers in nonalcoholic fatty liver disease.

Authors:  Manuela G Neuman; Lawrence B Cohen; Radu M Nanau
Journal:  Can J Gastroenterol Hepatol       Date:  2014-12

6.  4-HNE Immunohistochemistry and Image Analysis for Detection of Lipid Peroxidation in Human Liver Samples Using Vitamin E Treatment in NAFLD as a Proof of Concept.

Authors:  Maren C Podszun; Joon-Yong Chung; Kris Ylaya; David E Kleiner; Stephen M Hewitt; Yaron Rotman
Journal:  J Histochem Cytochem       Date:  2020-09       Impact factor: 2.479

Review 7.  History of Nonalcoholic Fatty Liver Disease.

Authors:  Amedeo Lonardo; Simona Leoni; Khalid A Alswat; Yasser Fouad
Journal:  Int J Mol Sci       Date:  2020-08-16       Impact factor: 5.923

8.  Molecular Interactions between NAFLD and Xenobiotic Metabolism.

Authors:  Adviti Naik; Aleš Belič; Ulrich M Zanger; Damjana Rozman
Journal:  Front Genet       Date:  2013-01-22       Impact factor: 4.599

9.  Noninvasive diagnosis of pediatric nonalcoholic fatty liver disease.

Authors:  Hye Ran Yang
Journal:  Korean J Pediatr       Date:  2013-02-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.